Peptic Ulcer Drugs Market Size

Gastrointestinal conditions such as gastritis, gastric ulcers, and duodenal ulcers or gastroesophageal reflux disease (GERD) are referred to as peptic ulcers. Drugs used to treat peptic ulcers include drugs that decrease the secretion of gastric ulcers, such as antagonists of the PPI and H2 receptors and acid neutralization agents such as antacids and antibiotics against H. Pylori. These medications, however, are also used in conjunction for successful treatment.

Market Highlights

Global Peptic Ulcer Drugs Market size was registered at USD 4.9 billion in 2019 and is estimated to reach USD 6.8 billion by 2030, registering a CAGR of 3.17 % from 2020 to 2030. Increasing the prevalence of peptic ulcers, increasing the adoption of peptic ulcer drugs over surgery, stimulating R&D through government policies, increasing the number of generic producers of peptic ulcer drugs, improvements in disease management, etc., are factors driving the growth of the global peptic ulcer market. Also, factors such as the increased prevalence of stress-induced ulcers due to changing lifestyle and diet increased smoking rates, and progressive geriatric population are anticipated to facilitate the expansion of the global market for peptic ulcer drugs

Global Peptic Ulcer Drugs Market Opportunity Analysis

Source: Fatpos Global

Global Peptic Ulcer Drugs Market: Segments

Peptic Ulcer Drugs Market is segmented based on disease indication, application, and region.

By Disease Indication (in %), Peptic Ulcer Drugs Market, 2019

The gastric ulcers segment is anticipated to register XX% of the market share during the forecasted period.

By disease indication, the market can be segmented into gastric ulcers, duodenal ulcers, and esophageal ulcers. Due to the high prevalence of diseases, the gastric ulcers segment is projected to account for a significant share of the global market during the forecast period.

By Application (in %), Peptic Ulcer Drugs Market, 2019

The hospital pharmacies segment accounted for XX% of the nation’s volume in 2019

The application segment can be classified into hospital pharmacies, drug stores, retail stores, and online sales. The hospital pharmaceuticals segment is projected to dominate the global market due to an increase in hospital numbers and a wide variety of services delivered at a single site.

Source: Fatpos Global

Global Peptic Ulcer Drugs Market Dynamics:

Increasing research and development and government policies to increase the market growth

Increasing the prevalence of peptic ulcers, increasing the adoption of peptic ulcer drugs over surgery, stimulating R&D through government policies, increasing the number of generic producers of peptic ulcer drugs, improvements in disease management, etc., are factors driving the growth of the global peptic ulcer market. Also, factors such as the increased prevalence of stress-induced ulcers due to changing lifestyle and diet, increased smoking rates, and progressive geriatric population is anticipated to facilitate the expansion of the global market for peptic ulcer drugs. The key driving factors for the drug market for peptic ulcers are stress, ulcers caused by medications, rising incidence of H.Pyrroli infection, improvements in food, increase in cancer, use of tobacco, and alcohol. Patent expiry, a comparatively good treatment regimen of proton pump inhibitors, H.Pyrolli resistance, severe market fragmentation in many businesses and wide generic penetration are constraining factors in this market.

Side effects related to ulcer medications and low efficiency to hinder the market growth

Factors expected to hamper the growth of the global peptic ulcer market over the forecast period are the side effects of peptic ulcer medications, low pipeline efficiency, and shifts in drug pricing policies.

Global Peptic Ulcer Drugs Market: Regions

In terms of value and volume, North America accounted for XX% of total market volume share in 2019

Global market share of peptic ulcer medications has been driven by North America, and this trend is expected to continue over the forecast period. Increased use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and increased awareness of peptic ulcer treatment options are factors that are expected to drive the growth of the North American market for peptic ulcer drugs. The second-largest share of the demand for peptic ulcer drugs in Europe is mainly due to the simple availability of effective treatment options for peptic ulcers in the country.

The region segment can be further divided into five major types including North America, Latin America, Europe, APAC, and MENA.

Source: Fatpos Global

Global Peptic Ulcer Drugs Market is further segmented by region into:

North America Market Size, Share, Trends, Opportunities-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Peptic Ulcer Drugs Market: Impact of COVID-19

Global pandemic COVID-19 has become global stress, not just for human lives, but also for industries across different industry verticals. The COVID-19 disease has infected several million people globally, with an increasing number of active cases daily, the duration of the pandemic is still difficult to predict. Because of the ongoing COVID-19 pandemic-an acute respiratory distress syndrome triggered by the novel coronavirus-the most unparalleled organizational and economic problems have arisen. Also, a substantial amount of time is needed to establish and market successful treatment options for this new COVID-19 pathogen. In the coming quarters of 2020 and 2021, these combined difficulties of infection transmission and treatment are expected to delay the diagnosis and treatment of GI disease. Reduced physician and hospital visits due to prioritization of COVID-19 care for non-essential health problems would hinder market development. Because of the availability of COVID-19 vaccines, the market for peptic ulcer medications is expected to rebound to pre-pandemic market demand in 2021. This will represent the COVID-19 pandemic in terms of recovering developed and emerging economies. Also, local governments prioritize healthcare services to meet the complexities of COVID-19, which is also projected to slow the pace of the demand for peptic ulcer medications in the short term.

Global Peptic Ulcer Drugs Market: Competitive landscape

New technological advancements in the Peptic Ulcer Drugs Market, as well as large production output of the product by key players, are likely to increase the market growth.

Peptic Ulcer Drugs Market: Key players

Eumedica
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Takeda Pharmaceutical Co. Ltd.
Taiho Pharmaceutical
Ferring Pharmaceuticals
PharmaKing
Zuventus Healthcare
Otsuka Holdings
Daiichi Sankyo
Johnson and Johnson
Other prominent players

Global Peptic Ulcer Drugs Market report also contains analysis on:

Peptic Ulcer Drugs Market segments: -

By Disease Indication:
- Gastric ulcers
- Duodenal ulcers
- Esophageal ulcers
By Application:
- Hospital Pharmacies
- Drug stores
- Retail stores
- Online sales
Peptic Ulcer Drugs Market dynamics
Peptic Ulcer Drugs Market size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints